| Literature DB >> 33685919 |
Moufida Ben Nasr1,2,3, Vera Usuelli2, Andy Joe Seelam2, Francesca D'Addio2, Reza Abdi3, James F Markmann4, Paolo Fiorina5,2,6.
Abstract
Since they were discovered almost three decades ago, a subset of B cells denoted as regulatory B cells (Bregs) have elicited interest throughout the immunology community. Many investigators have sought to characterize their phenotype and to understand their function and immunosuppressive mechanisms. Indeed, studies in murine models have demonstrated that Bregs possess varied phenotypic markers and could be classified into different subsets whose action and pivotal role depend on the pathological condition or stimuli. Similar conclusions were drawn in clinical settings delineating an analogous Breg population phenotypically resembling the murine Bregs that ultimately may be associated with a state of tolerance. Recent studies suggested that Bregs may play a role in the onset of autoimmune diabetes. This review will focus on deciphering the different subclasses of Bregs, their emerging role in autoimmune diabetes, and their potential use as a cell-based therapeutic.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33685919 DOI: 10.4049/jimmunol.2001127
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422